A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

Trial Details

NCT ID
NCT06022029
Phase
PHASE1
Sponsor
OncoNano Medicine, Inc.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Tamarac, Florida, United States|26.21286,-80.24977
  • Canton, Ohio, United States|40.79895,-81.37845
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Ability to understand and willingness to sign written informed consent before performance of any study procedures
  • Age ≥ 18 years
  • Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or …
  • Participants must have a minimum of one injectable and measurable lesion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →